BOTHELL, Wash., Aug.  17, 2026  (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) (&#34;Cocrystal&#34; or the &#34;Company&#34;), a clinical-stage biotechnology company developing novel therapeutics to meet the

COCP

Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors

Cocrystal Pharma adds antiviral veteran to Board, signaling pipeline focus

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>BOTHELL, Wash., Aug.  17, 2026  (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) (&amp;#34;Cocrystal&amp;#34; or the &amp;#34;Company&amp;#34;), a clinical-stage biotechnology company developing novel therapeutics to meet the</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>COCRystal Pharma (COCP) announced the appointment of Dr. Carol Brosgart to its Board on August 12, 2026, adding a veteran antiviral expert. The move signals stronger governance and potential strategic guidance for CDI-988 and the broader antiviral pipeline, leveraging her experience at Gilead and with the CDC. Near-term price movement will hinge on pipeline milestones and any upcoming clinical or partnership news.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>COCP appoints Dr. Carol Brosgart to Board. Effective Aug 12, 2026.</li><li>Dr. Brosgart brings decades in antiviral therapy and policy.</li><li>Background includes Gilead and CDC roles; strengthens antiviral leadership.</li><li>No immediate clinical data; catalysts depend on CDI-988 progress.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Cocrystal Pharma, Inc. (COCP)</strong>: News pertains to governance; potential impact on strategic execution.</li><li><strong>Gilead Sciences, Inc. (GILD)</strong>: Former employer of Dr. Brosgart; antiviral-development pedigree may influence perception.</li><li><strong>Galmed Pharmaceuticals, Ltd. (GLMD)</strong>: Dr. Brosgart sits on Galmed&#039;s board; demonstrates antiviral-network relevance.</li><li><strong>Mirum Pharmaceuticals, Inc. (MIRM)</strong>: Board affiliation noted; broader governance connections in antiviral space.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. Board changes in biotech signaling leadership depth; relevant for COCP&#039;s execution of its antiviral pipeline.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Governance upgrade may lift sentiment and stock visibility.</li><li>No near-term clinical data; catalysts rely on CDI-988 progress.</li><li>Antiviral-focused leadership could attract biotech investors and funds.</li><li>Small-cap biotech volatility remains a factor.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Effective August 12, 2026, Dr. Carol Brosgart joined COCP&#039;s Board.</li><li>Dr. Brosgart has decades of antiviral therapy experience and policy work.</li><li>Previously at Gilead Sciences; contributed to Viread and Hepsera developments.</li><li>Currently on boards of Galmed Pharmaceuticals, Eradivir Biotech, and Merlin Biotech.</li><li>COCP&#039;s focus includes CDI-988 for norovirus and broader antiviral programs.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term bullish drift possible on governance signal; monitor CDI-988 milestones over the next 2–4 quarters.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">BOTHELL, Wash., Aug.  17, 2026  (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/COCP">COCP</a>) (&#34;Cocrystal&#34; or the &#34;Company&#34;), a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments, today announced the appointment of Carol Brosgart, MD to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings several decades of experience in antiviral therapy, epidemiology, and biopharma advisory.</p>  <p align="justify">&#34;Dr. Brosgart holds a distinguished record in antiviral drug development, having contributed to the development and FDA approval of therapies that have benefited patients worldwide," said Roger Kornberg, Ph.D., Chairman of the Board, Chief Scientist, and Chairman of Scientific Advisory Board at Cocrystal and Nobel laureate. "Her clinical and scientific insights will be invaluable as we work to advance the clinical development of CDI-988 for norovirus, as well as the broader development of our antiviral pipeline.&#34;</p>  <p align="justify">James Sapirstein, Chief Executive Officer of Cocrystal Pharma added, &#34;I&#39;ve had the privilege of knowing Carol since she was a key opinion leader during the HIV epidemic, working with her as a colleague at Gilead, and later having her join me at Tobira. Few people bring her combination of clinical rigor and real-world drug development experience, and I couldn&#39;t be more pleased to have her insight guiding Cocrystal at this pivotal stage.&#34;</p>  <p align="justify">Dr. Brosgart has extensive experience in government service and biopharmaceutical consulting, has served on the boards of numerous biotechnology companies, and was the founding Medical Director of the East Bay AIDS Center at Alta Bates Medical Center in Berkeley, California. She is a member of the Board of Directors of the Hepatitis B Foundation, previously co-chaired the National Task Force on Hepatitis B and was a Senior Advisor on Science and Policy to the Division of Viral Hepatitis at the CDC and the Viral Hepatitis Action Coalition at the CDC Foundation. She currently sits on the Boards of Directors of Galmed Pharmaceuticals, Eradivir Biotech, and Merlin Biotech, and previously held board positions at Abivax, Mirum Pharmaceuticals, Tobira Therapeutics and Juvaris. Dr. Brosgart spent more than a decade at Gilead Sciences as well, where she played a critical role in the development and regulatory approval of the antiviral therapies Viread<sup>&#xAE;</sup> and Hepsera<sup>&#xAE;</sup>. She received her M.D. from the University of California, San Francisco (UCSF) School of Medicine, where she currently serves as a Clinical Professor of Medicine, Biostatistics and Epidemiology.</p>  <p align="justify"><b>About Cocrystal Pharma, Inc. </b><br></br>Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of noroviruses, influenza viruses, coronaviruses (including SARS-CoV-2), and hepatitis C viruses. Cocrystal employs unique structure-based technologies to create viable antiviral drugs. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=RHUhK7ywnQ6Lb_6VKYYERAjcIyDpLXlPznGbpabUy-ooXxU2jpnBfiQYEm2AgIiOlQuxWi5XfStca8MwJBZPlG8PytXX-2wQMYWMwFE0KxA=" rel="nofollow" target="_blank">www.cocrystalpharma.com</a>.</p>  <p align="justify"><b>Investor Contact:</b><br></br>Nic Johnson<br></br>Russo Partners<br></br><a href="https://www.globenewswire.com/Tracker?data=eVOjgqyuvUV6xgt6CpAGHvAiN77BMji3XnGb-v6XQkuiKiDt22v8sz4kN6_Bjw8Hr8v1_LXf8eypgbqhpEvqsc_LDR3GKKbcYHOx8gG9He-gGwfsf3wO50TkwtxWph8y7fNIcqcD4_X31dFiBRPluA==" rel="nofollow" target="_blank">nic.johnson@russopartnersllc.com</a><br></br>(303) 482-6405</p>  <p align="justify"><b>Media Contact:</b><br></br>David Schull<br></br>Russo Partners<br></br><a href="https://www.globenewswire.com/Tracker?data=_ulmMtzQM8llpaG2HYkDHsxwO5FLXJ3Xl0Ov5iuN8_0QEpRNHyu8KL4s5tVgtccBMgiBPBBViD1a7YDhL7GC6YgMXyC5BjPHHYOHLVjKg8rCylCPTFWH2ww-qK5PHOAEMVuyv_-ec6-ZLB2DYMXzLw==" rel="nofollow" target="_blank">david.schull@russopartnersllc.com</a><br></br>(858) 717-2310</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTgxMTI4MSM3Nzc5OTIwIzIwODQyNzg="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ZWJlMWNjZmEtMzE1Ny00MzgzLWEwMjAtYTlhZTk0MjVkZTc5LTEwOTU4NDktMjAyNi0wOC0xNy1lbg==/tiny/Cocrystal-Pharma-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/a5071a3a-c592-43ba-bfee-77c2867982ba"><img src="https://ml.globenewswire.com/media/a5071a3a-c592-43ba-bfee-77c2867982ba/small/cocrystal-logo-final-highres-792x612-png.png" border="0" width="150" height="116" alt="Primary Logo"></img></a></p>

COCRystal Pharma (COCP) announced the appointment of Dr. Carol Brosgart to its Board on August 12, 2026, adding a veteran antiviral expert. The move signals stronger governance and potential strategic guidance for CDI-988 and the broader antiviral pipeline, leveraging her experience at Gilead and with the CDC. Near-term price movement will hinge on pipeline milestones and any upcoming clinical or partnership news.

News insight

Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors

AI summary

Sentiment rationale

Key facts

Corporate Developments